Who have Lipoatrophy with Escitalopram - from FDA reports


Lipoatrophy is reported only by a few people who take Escitalopram. We study 28,119 people who have side effects while taking Escitalopram from FDA. Among them, 2 have Lipoatrophy. Find out below who they are, when they have Lipoatrophy and more.

How to use this study: bring a copy to your health teams to ensure drug risks and benefits are fully discussed and understood.

Who is eHealthMe: we are a data analysis company who specializes in health care industry. Our original studies have been referenced on 500+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and EANO. On eHealthMe, you can research drugs and monitor them (see testimonials). If you find eHealthMe useful, please help us to spread the words below or leave us a testimonial.



On Dec, 06, 2018

28,119 people reported to have side effects when taking Escitalopram.
Among them, 2 people (0.01%) have Lipoatrophy


Number of reports submitted per year:

Could Escitalopram cause Lipoatrophy?

Gender of people who have Lipoatrophy when taking Escitalopram *:

  • female: 0.0 %
  • male: 100 %

Top conditions involved for these people *:

  1. Hiv Infection: 1 person, 50.00%

Top co-used drugs for these people *:

  1. Lamivudine: 2 people, 100.00%
  2. Kaletra: 2 people, 100.00%
  3. Didanosine: 2 people, 100.00%

Top other side effects for these people *:

  1. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs): 2 people, 100.00%
  2. Lipodystrophy Acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired): 2 people, 100.00%

* Approximation only. Some reports may have incomplete information.

FDA reports used in this study



Do you have Lipoatrophy while taking Escitalopram?


You are not alone:




Related studies

Escitalopram

Escitalopram has active ingredients of escitalopram oxalate. It is often used in depression. (latest outcomes from Escitalopram 29,849 users)

Lipoatrophy

Lipoatrophy (localized loss of fat tissue) has been reported by people with hiv infection, multiple sclerosis, type 1 diabetes, diabetes, rheumatoid arthritis (latest reports from 818 Lipoatrophy patients).


Drugs that are associated with Lipoatrophy
Lipoatrophy (278 drugs)
Could your condition cause Lipoatrophy
Lipoatrophy (140 conditions)
Escitalopram side effects
Browse all side effects of Escitalopram
a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


What would happen?

Predict new side effects and undetected conditions when you take Escitalopram and have Lipoatrophy


Recent updates

Recent general studies
Recent personal studies

NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Submit your testimonial

  • Please fill in your Testimonial.
  • Please enter a minimum of 10 characters for your Testimonial.
  • Please fill in your Name.

Please wait...

{progressItem}

Thank you!